Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) is scheduled to be releasing its earnings data on Monday, August 14th. Analysts expect Syros Pharmaceuticals to post earnings of ($0.55) per share for the quarter.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Monday, May 15th. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.10. The firm had revenue of $1.10 million during the quarter. On average, analysts expect Syros Pharmaceuticals to post $-2.15 EPS for the current fiscal year and $-3.13 EPS for the next fiscal year.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) opened at 22.13 on Monday. The company has a 50-day moving average of $18.30 and a 200-day moving average of $14.85. The firm’s market cap is $579.36 million. Syros Pharmaceuticals, Inc. has a 1-year low of $8.16 and a 1-year high of $24.31.

WARNING: “Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Set to Announce Earnings on Monday” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/08/07/syros-pharmaceuticals-inc-nasdaqsyrs-set-to-announce-earnings-on-monday.html.

Several brokerages have commented on SYRS. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. ValuEngine raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Oppenheimer Holdings, Inc. set a $28.00 target price on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, June 12th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $22.00 target price on shares of Syros Pharmaceuticals in a research note on Tuesday, May 16th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $20.67.

In other news, Director Richard A. Young sold 3,282 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $22.09, for a total value of $72,499.38. Following the completion of the transaction, the director now owns 423,383 shares in the company, valued at $9,352,530.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric R. Olson sold 12,500 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $21.85, for a total transaction of $273,125.00. Following the completion of the transaction, the insider now owns 12,500 shares of the company’s stock, valued at approximately $273,125. The disclosure for this sale can be found here.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.